Skip to main content
Journal cover image

The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.

Publication ,  Journal Article
Sartor, O; McLeod, DG; Halabi, S; Schellhammer, PF; Scardino, PT; D'Amico, AV; Bennett, C; Wei, JT; COMPARE Registry Steering Committee,
Published in: Urology
March 2010

OBJECTIVES: To define current standards of care for patients with prostate-specific antigen (PSA) failure after initial definitive local treatment of prostate cancer using Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry (COMPARE). This article describes the design of the COMPARE Registry, together with patient characteristics and prostate cancer management at enrolment. METHODS: The COMPARE Registry is a prospective, multicenter, observational study that collected data on patient characteristics, management practices, and outcomes of men presenting to their physician for the management of an increasing PSA level after definitive (surgical or radiotherapeutic) treatment of localized prostate cancer. Data collected by the physician and reported by the patient at the baseline (enrolment) visit are described. RESULTS: Between February 2004 and March 2007, 1120 men were enrolled at 150 sites throughout the United States. The men had a median age of 73 years (range, 46-95 years), were predominantly white (77%), and had a median PSA level of 7.9 ng/mL (range, 0-710.8 ng/mL) at diagnosis. Observation (74%) was the most common initial management choice at registry enrolment, and androgen-deprivation therapy (22%) was the most common initial treatment choice. CONCLUSIONS: Data from the COMPARE Registry should provide a valuable source of prospectively collected information on the contemporary management of prostate cancer and patient outcomes after PSA failure.

Duke Scholars

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

March 2010

Volume

75

Issue

3

Start / End Page

623 / 629

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Treatment Failure
  • Registries
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prospective Studies
  • Multicenter Studies as Topic
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sartor, O., McLeod, D. G., Halabi, S., Schellhammer, P. F., Scardino, P. T., D’Amico, A. V., … COMPARE Registry Steering Committee, . (2010). The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology, 75(3), 623–629. https://doi.org/10.1016/j.urology.2009.04.059
Sartor, Oliver, David G. McLeod, Susan Halabi, Paul F. Schellhammer, Peter T. Scardino, Anthony V. D’Amico, Charles Bennett, John T. Wei, and John T. COMPARE Registry Steering Committee. “The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.Urology 75, no. 3 (March 2010): 623–29. https://doi.org/10.1016/j.urology.2009.04.059.
Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D’Amico AV, et al. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar;75(3):623–9.
Sartor, Oliver, et al. “The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.Urology, vol. 75, no. 3, Mar. 2010, pp. 623–29. Pubmed, doi:10.1016/j.urology.2009.04.059.
Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D’Amico AV, Bennett C, Wei JT, COMPARE Registry Steering Committee. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar;75(3):623–629.
Journal cover image

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

March 2010

Volume

75

Issue

3

Start / End Page

623 / 629

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Treatment Failure
  • Registries
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prospective Studies
  • Multicenter Studies as Topic
  • Male
  • Humans